Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
151 Results for "
lung function
" in MedChemExpress (MCE) Product Catalog:
Products (151)
151 Results for "lung function" in MCE Product Catalog:
Cat. No.: HY-19896A
CAS No.: 1204956-74-0
Target:
Research Areas:
COTI-2 hydrochloride is an orally active thiosemicarbazone anticancer agent and p53 mutant activator. COTI-2 hydrochloride induces Apoptosis. COTI-2 hydrochloride triggers the activation of AMPK and the inhibition of the mTOR pathway. COTI-2 hydrochloride induces DNA damage and replication stress responses. COTI-2 hydrochloride binds to misfolded mutant p53 proteins, thereby inducing conformational changes that restore p53 to its normal state and reactivate its function. COTI-2 hydrochloride acts on a variety of cancer cell lines and xenografts. COTI-2 hydrochloride can be used in research related to colorectal cancer, small cell lung cancer, glioblastoma, breast cancer, and ovarian cancer .
Cat. No.: HY-N6678S
CAS No.: 1795020-90-4
Target:
Research Areas:
2,5-Anhydro-D-glucitol-1,6-diphosphate is a competitive PFK-1 inhibitor. 2,5-Anhydro-D-glucitol-1,6-diphosphate inhibits the enzymatic activity of PFKP without altering the non-glycolytic regulatory function of PFKP. 2,5-Anhydro-D-glucitol-1,6-diphosphate does not change mitochondrial AMPK levels, ACC2 phosphorylation levels, long-chain free fatty acid levels, or ROS levels under glucose starvation conditions. 2,5-Anhydro-D-glucitol-1,6-diphosphate is used in related research on non-small cell lung cancer .
Cat. No.: HY-175033
Research Areas:
BRD4-IN-11 is an orally active and selective BRD4 inhibitor (IC50 = 26.35 nM (BD1), IC50 = 72.81 nM (BD2)). BRD4-IN-11 is approximately 3- to 18-fold more potent against BRD4 than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis .
Cat. No.: HY-181646
CAS No.: 3052591-16-6
Target:
Research Areas:
PDE4-IN-34 is a phosphodiesterase 4 (PDE4) inhibitor, with IC50 values of 19 pM and 14 pM against PDE4B1 and PDE4D2, respectively. PDE4-IN-34 shows weak inhibitory activity against PDE8A1, with an IC50 value of 4.092 μM, and exhibits significant selectivity over other subtypes (IC50 > 10 μM). PDE4-IN-34 improves pulmonary function, reduces inflammatory responses and alleviates lung tissue damage in a rat model induced by cigarette smoke combined with LPS (HY-D1056). PDE4-IN-34 can be used for research related to chronic obstructive pulmonary disease .
Cat. No.: HY-19108
CAS No.: 104795-68-8
Target:
Research Areas:
CI-959 is an orally active cell activation inhibitor. CI-959 selectively suppresses inflammatory cell activation post-receptor signaling via inhibiting calcium influx and weak calmodulin antagonism, without targeting PLC, PKC or NADPH oxidase. CI-959 blocks lung allergic mediator release, anti-IgE bronchial contraction, neutrophil function, T-cell proliferation and DC marker expression while sparing monocytes. CI-959 provides gastric cytoprotection by inhibiting leukocyte adhesion and suppresses tumor motility through F-actin reduction. CI-959 can be used for research on allergies, inflammation, autoimmune diseases, gastric injury, and tumor metastasis .
Cat. No.: HY-N1508
CAS No.: 78285-90-2
Cat. No.: HY-N3225
CAS No.: 33606-81-4
Category:
Cat. No.: HY-P991740
Target:
Research Areas:
Cat. No.: HY-P992291
Cat. No.: HY-113886
CAS No.: 104795-66-6
Target:
Research Areas:
CI-959 free acid is an orally active cell activation inhibitor. CI-959 free acid selectively suppresses inflammatory cell activation post-receptor signaling via inhibiting calcium influx and weak calmodulin antagonism, without targeting PLC, PKC or NADPH oxidase. CI-959 free acid blocks lung allergic mediator release, anti-IgE bronchial contraction, neutrophil function, T-cell proliferation and DC marker expression while sparing monocytes. CI-959 free acid provides gastric cytoprotection by inhibiting leukocyte adhesion and suppresses tumor motility through F-actin reduction. CI-959 free acid can be used for research on allergies, inflammation, autoimmune diseases, gastric injury, and tumor metastasis .
Cat. No.: HY-161577
CAS No.: 701231-39-2
Target:
Research Areas:
BFC1103 is a small-molecule compound whose primary mechanism of action involves interaction with a specific domain of Bcl-2, particularly its loop domain. This interaction induces a conformational change in Bcl-2, exposing its BH3 (Bcl-2 homology 3) domain, thereby switching Bcl-2's function from anti-apoptotic to pro-apoptotic. The cell death induced by BFC1103 is dependent on the presence of Bax or Bak, both of which are key proteins involved in the intrinsic apoptotic pathway mediated by mitochondria. BFC1103 has successfully inhibited lung metastasis of triple-negative breast cancer in mouse models. It can be utilized in studying the roles of Bcl-2 family proteins in cancer development and how they impact the survival and proliferation of cancer cells .
Cat. No.: HY-189471
VEGFR2/C-RAF kinase-IN-1 is a type II dual kinase inhibitor targeting VEGFR2 and C-RAF, with IC50 values of 12.22 nM and 38.04 nM, respectively. VEGFR2/C-RAF kinase-IN-1 binds VEGFR2 and CRAF in a Type-II mode and inhibits the downstream Raf-MEK-ERK signaling cascade. VEGFR2/C-RAF kinase-IN-1 induces cell cycle arrest, apoptosis, and intracellular ROS accumulation in H1299 cells, while partially inhibiting P-gp efflux function. VEGFR2/C-RAF kinase-IN-1 can be used for cancer research, such as non-small cell lung cancer and liver cancer .
Cat. No.: HY-N10093
CAS No.: 69618-96-8
Synonyms: Chamaejasmin
Cat. No.: HY-N1508R
CAS No.: 78285-90-2
Category:
Cat. No.: HY-P991097
Synonyms: PM-8002; BNT-327
Target:
Research Areas:
Cat. No.: HY-112726A
CAS No.: 1478364-40-7
Synonyms: BI-1467335 free base
Research Areas:
PXS-4728A free base is an orally active, selective VAP-1/SSAO inhibitor with an IC50 of 5 nM and a Ki of 175 nM. PXS-4728A free base inhibits the expression of MMP-9. It reduces cell rolling, adhesion and migration, decreases cell infiltration levels, pro-inflammatory cytokines, chemokines and collagen deposition, and improves pulmonary function. PXS-4728A free base reduces the formation and progression of atherosclerotic plaques, and decreases blood lipid and blood glucose levels as well as body weight gain. PXS-4728A free base can be used in research related to chronic obstructive pulmonary disease, cystic fibrosis, acute pulmonary inflammation, acute lung injury, bronchiolitis obliterans syndrome, rhinovirus-exacerbated asthma, sepsis, Klebsiella pneumoniae pulmonary infection and atherosclerosis .
Cat. No.: HY-183246
CAS No.: 2143950-05-2
Target:
Research Areas:
Rac/Cdc42-IN-1, the major phase I metabolite of the oral Rac/Cdc42 inhibitor MBQ-167 (HY-112842) in vivo, is a selective Rac inhibitor. Rac/Cdc42-IN-1 functions by blocking the GTP-binding activation of Rac1, targeting the autophosphorylation of Thr 423/Thr 402/Thr 436 and Ser 141/Ser 144/Ser 154 in downstream PAK1/2/3, with an inhibitory effect superior to that of MBQ-167. Rac/Cdc42-IN-1 significantly inhibits cell migration, and suppresses tumor growth and distant metastasis to the lung, liver and kidney in HER2+ breast cancer mouse models. Rac/Cdc42-IN-1 can be used for targeted research on metastatic breast cancer .
Cat. No.: HY-187335
Target:
Research Areas:
HadAB/InhA=IN-1 is a dual inhibitor of Mycobacterium tuberculosis InhA and HadAB with an InhA IC50 of 0.81 μM. HadAB/InhA=IN-1 inhibits InhA enzymatic activity in the FAS-II pathway of mycolic acid biosynthesis. HadAB/InhA=IN-1 undergoes EthA-mediated activation to covalently bind HadA and inhibit HadAB dehydratase function in the same FAS-II pathway. HadAB/InhA=IN-1 reduces mycolic acid-containing lipid and mycolic acid production, and accumulates standard fatty acids in Mycobacterium tuberculosis. HadAB/InhA=IN-1 exhibits antimycobacterial activity against drug-susceptible, ethA-deficient, and multi-drug-resistant Mycobacterium tuberculosis isolates. HadAB/InhA=IN-1 shows cytotoxic effects against human cancer and immortalized normal lung fibroblast cells. HadAB/InhA=IN-1 can be used for the research of tuberculosis .
Cat. No.: HY-N0732R
CAS No.: 37905-08-1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
